PTGX Stock Analysis: Buy, Sell, or Hold?
PTGX - Protagonist Therapeutics, Inc
$122.15
3.19 (2.68%)
▲
5d:
+10.4%
30d:
+23.15%
90d:
+21.68%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When PTGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PTGX is 11.8% above its trading range ($109.22). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PTGX is 11.8% above its trading range ($109.22). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PTGX is currently trading at $122.15, which is considered extended relative to its 30-day fair value range of $97.39 to $109.22. From a valuation perspective, the stock is trading at a discount (Forward PE: -178.4) compared to its historical average (83.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PTGX is in a uptrend. The price is approaching resistance at $123.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTGX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PTGX is in a uptrend. The price is approaching resistance at $123.93. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTGX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$97.39 -
$109.22
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
PTGX is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+11.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($118.69)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$97.39 -
$109.22
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$104.89
Resistance Level
$123.93
Current Trend
Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-178.40
Wall Street Target
$118.69
(-2.8%)
Revenue Growth (YoY)
99.0%
Earnings Growth (YoY)
351.3%
Profit Margin
-154.9%
PE vs Historical
-178.4 vs 83.6
CHEAP
Share & Embed Analysis
Last updated: June 25, 2026 3:08 AM ET
Data refreshes hourly during market hours. Next update: 4:08 AM
Data refreshes hourly during market hours. Next update: 4:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Asif Ali
SELL
1750 shares
2026-04-20
Arturo Md Molina
SELL
15000 shares
2026-03-26
Asif Ali
SELL
24765 shares
2026-03-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 58 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$57 | 64 BUY |
Advanced PTGX Option Strategies
Professional options setups generated by AI based on today's PTGX price and gamma walls.
